byl719 and Carcinoma--Ductal--Breast

byl719 has been researched along with Carcinoma--Ductal--Breast* in 1 studies

Other Studies

1 other study(ies) available for byl719 and Carcinoma--Ductal--Breast

Article	Year
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation]. Bulletin du cancer, 2020, Volume: 107, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles	2020

Article

Year

[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].

Bulletin du cancer, 2020, Volume: 107, Issue:10

Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles

2020